Новые возможности повышения эффективности лечения артериальной гипертензии

1. Рекомендации РМОАГ/ВНОК по диагностике и лечению артериальной гипертонии (четвертый пересмотр), 2010.
2. Dahlо..f B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895–906.
3. Bakris et al. Average no of antihypertensive medications Am J Med 2004; 116 (5A): 30S–8.
4. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34: 2159–219.
5. Jamerson K, Weber A, Bakris GL et al. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients for the ACCOMPLISH Trial nvestigators. N Engl J Med 2008; 359: 2417–28.
6. Angeli F et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am
 J Hypertens 2004; 17 (9): 817–22.
7. Angelico P, Guarneri L, Leonardi A et al. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues.
 J Pharmacol 1999; 51: 709–14.
8. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): 95–100.
9. Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. 
J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S50–3.
10. Barbagallo M, Barbagallo SG. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.
11. Zanchetti A. Emerging data on calcium-channel blockers: the COHORT study. Clin Cardiol 2003; 26 (Suppl. 2): II 17–20.
12. Borghi C, Prandin MG, Dormi A. The use of lercanidipine can improve the individual tolerability to dihydropyridine calcium blockers in hypertensive patients [abstract]. J Hypertens 2000; 18 (Suppl. 2): S155.
13. Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348 (7): 583–92.
14. Vermes E, Tardif JC, Bourassa MG et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight fr om the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107 (9): 1291–6.
15. Vermes E, Tardif JC, Bourassa MG et al. Enalapril reduces the incidence of atrial fibrillation in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107 (9): 2926–31.
16. Puig  JG, Calvo C, Luurila O et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study. J Hum Hypertens 2007; 21: 917–24.
17. Hair PI, Scott LJ, Perry CM. Fixed-dose combination lercanidipine/enalapril. Drugs 2007; 67: 95–106.
18. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006; 24: 185–92.
19. Rump LC. Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension. Arzneimittelforschung 2010; 60: 124–30.
20. Scholze J, Bramlage P, Trenkwalder P, Kreutz R. Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opin Pharmacother 2011; 12 (18): 2771–9.
21. Quarti F, Seravalle G, Dell Oro R et al. Effects of lercanidipine/enelapril combination on neurometabolic alterations in obese hypertensive subjects. High blood pressure Cardiovasc Prev 2010; 17 (3): 1120.
22. Dworkin LD. Effects of calcium channel blockers on experimental glomerular injury. J Am Soc Nephrol 1990; 1: S21–7.
23. Praga M, Fernandez Andrade C, Lun~o J et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomised clinical trial. Nephrol Dial Transplant 2003; 18: 1806–13.
24. Viberti G. Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure – Independent Effect. Wheeldon and for the Microalbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Circulation 2002; 106: 672–8.
25. Kloke HJ et al. Meta-analysis of changes in albuminuria and arterial pressure in hypertensive patients with proteinuria in studies wh ere patients received nifedipine, any other DHP CCB, a non-DHP CCB, or an ACE inhibitor. Kidney Int 1998; 53: 1559–73.
26. Herlitz H, Harris K, Risler T et al. The eff ects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001; 16: 2158–65.
27. Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004; 17 (5): 259–66.
28. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA study. Ren Fail 2005; 27 (1): 73–80.
29. Egan CG, Pontremoli R. Role of the fixed combination lercanidipine/enalapril in renal protection. J Nephrol 2011; 24: 428–37.

Г.А.Барышникова, С.А.Чорбинская, И.И.Степанова

ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России, Москва